[Federal Register: February 18, 2004 (Volume 69, Number 32)]
[Notices]               
[Page 7656]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr18fe04-64]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 25,2003, Irix 
Pharmaceuticals, Inc., 101 Technology Place, Florence, South Carolina 
29501, made application by renewal to the Drug Enforcement 
Administration (DEA) for registration as a bulk manufacturer of 
methylphenidate (1724), a basic class of controlled substance listed in 
Schedule II.
    The firm plans to manufacture methylphenidate for sale to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substance may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than April 19, 
2004.

    Dated: February 4, 2004.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-3480 Filed 2-17-04; 8:45 am]

BILLING CODE 4410-09-M